Many people experience cognitive changes including difficulty concentrating, memory problems, or mental fogginess
19 :1-5 Key words: type 2 diabetes, cardiovascular outcome studies, pioglitazone, SGLT2 inhibitors, GLP-1 receptor agonist In previous editorials 1-4 we proposed that metformin, pioglitazone, sodium glucose transporter 2 (SGLT2) inhibitors (in particular empagliflozin and canagliflozin) and long-acting glucagon-like peptide-1 (GLP-1) receptor agonists (in particular liraglutide) in combination could complement each other to prevent cardiovascular events and save lives in patients with type 2 diabetes at high cardiovascular risk
The paradox: GLP-1 agonists as both pain cause and pain treatment Here is where the semaglutide-allodynia story becomes genuinely interesting
Instead of dealing with fluctuating costs or financing applications, you pay a predictable monthly fee
For patients managing diabetes with insulin or sulfonylureas alongside GLP-1 therapy, hypoglycemia becomes a concern
